Nuvalent to Discuss Pivotal Data for Neladalkib in Advanced ALK-positive NSCLC

Nuvalent will host a webcast and conference call on November 17, 2025 to discuss topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial. Neladalkib is designed to overcome limitations of currently available ALK inhibitors and has received FDA breakthrough therapy designation for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have been previously treated with 2 or more ALK tyrosine kinase inhibitors.